These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18952760)

  • 1. Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
    Chaigneau L; Royer B; Montange D; Nguyen T; Maurina T; Villanueva C; Demarchi M; Borg C; Fagnoni-Legat C; Kantelip JP; Pivot X
    Ann Oncol; 2008 Nov; 19(11):1980-1. PubMed ID: 18952760
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
    Daher Abdi Z; Lavau-Denes S; Prémaud A; Urien S; Sauvage FL; Martin J; Leobon S; Marquet P; Tubiana-Mathieu N; Rousseau A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1285-93. PubMed ID: 24801171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
    Chachad S; Purandare S; Malhotra G; Naidu R
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):287-92. PubMed ID: 23090620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
    Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
    Honda J; Sasa M; Moriya T; Bando Y; Hirose T; Takahashi M; Nagao T; Tangoku A
    J Med Invest; 2008 Feb; 55(1-2):54-60. PubMed ID: 18319546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
    Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
    Milano G; Ferrero JM; François E
    Br J Cancer; 2004 Aug; 91(4):613-7. PubMed ID: 15280932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer.
    Ben-Josef E
    Am J Clin Oncol; 2007 Dec; 30(6):649-55. PubMed ID: 18091061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal drug-drug interaction of brivudine and capecitabine.
    Rätz Bravo AE; Hofer S; Krähenbühl S; Ludwig C
    Acta Oncol; 2009; 48(4):631-3. PubMed ID: 19165642
    [No Abstract]   [Full Text] [Related]  

  • 11. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
    Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
    Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
    Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):571-2. PubMed ID: 12503818
    [No Abstract]   [Full Text] [Related]  

  • 13. [The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
    Moiseenko VM; Semenova AI; Orlova RV
    Vopr Onkol; 2001; 47(1):112-9. PubMed ID: 11317529
    [No Abstract]   [Full Text] [Related]  

  • 14. Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
    Clin Colorectal Cancer; 2007 Mar; 6(6):407-22. PubMed ID: 17539192
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral capecitabine (Xeloda) in cancer treatment.
    Doyle DP; Engelking C
    Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
    [No Abstract]   [Full Text] [Related]  

  • 16. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
    Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
    Gore L; Holden SN; Cohen RB; Morrow M; Pierson AS; O'Bryant CL; Persky M; Gustafson D; Mikule C; Zhang S; Palmer PA; Eckhardt SG
    Ann Oncol; 2006 Nov; 17(11):1709-17. PubMed ID: 16980604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of capecitabine: a review.
    Mikhail SE; Sun JF; Marshall JL
    Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oral fluoropyrimidines in cancer chemotherapy.
    Lamont EB; Schilsky RL
    Clin Cancer Res; 1999 Sep; 5(9):2289-96. PubMed ID: 10499595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
    Alexandre J; Kahatt C; Bertheault-Cvitkovic F; Faivre S; Shibata S; Hilgers W; Goldwasser F; Lokiec F; Raymond E; Weems G; Shah A; MacDonald JR; Cvitkovic E
    Invest New Drugs; 2007 Oct; 25(5):453-62. PubMed ID: 17628744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.